Advertisement

L’Endocrinologo

, Volume 13, Issue 4, pp 150–157 | Cite as

I nuovi farmaci per la terapia dell’osteoporosi

Proposto da Salvatore Minisola
  • Francesco Bertoldo
  • Serena Pancheri
Article

Riassunto

L’osteoporosi è una malattia dello scheletro caratterizzata da bassa densità minerale ossea, scarsa qualità dell’osso e aumentato rischio di fratture. Le recenti conoscenze fisiopatologiche sui meccanismi cellulari e molecolari dell’osteoporosi hanno spostato l’attenzione dello sviluppo farmaceutico dal classico bersaglio degli osteoclasti, agli osteoblasti e agli osteociti. In questa review analizzeremo brevemente i farmaci approvati o in fase di studio per tale patologia.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Bibliografia

  1. 1.
    Melton LJ 3rd, Kearns AE, Atkinson EJ, et al 2009 Secular trends in hip fracture incidence and recurrence. Osteoporos Int 20:687–694.PubMedCentralPubMedCrossRefGoogle Scholar
  2. 2.
    Black DM, Delmas PD, Eastell R, et al; HORIZON Pivotal Fracture Trial 2007 Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809–1822.PubMedCrossRefGoogle Scholar
  3. 3.
    Grey A, Bolland MJ, Horne A, et al 2012 Five years of anti-resorptive activity after a single dose of zoledronate — Results from a randomized double-blind placebo-controlled trial. Bone 50:1389–1393.PubMedCrossRefGoogle Scholar
  4. 4.
    Neer RM, Arnaud CD, Zanchetta JR, et al 2001 Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434–1441.PubMedCrossRefGoogle Scholar
  5. 5.
    Hodsman AB, Bauer DC, Dempster DW, et al 2005 Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr Rev 26:688–703.PubMedCrossRefGoogle Scholar
  6. 6.
    Meunier PJ, Roux C, Seeman E, et al 2004 The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 350:459–468.PubMedCrossRefGoogle Scholar
  7. 7.
    Reginster JY, Seeman E, De Vernejoul MC, et al 2005 Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab 90:2816–2822.PubMedCrossRefGoogle Scholar
  8. 8.
    Miller PD, Wagman RB, Peacock M, et al 2011 Effect of denosumab on bone mineral density and biochemical markers of bone turnover: six-year results of a phase 2 clinical trial. J Clin Endocrinol Metab 96:394–402.PubMedCrossRefGoogle Scholar
  9. 9.
    Cummings SR, San Martin J, McClung MR, et al 2009 Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361:756–765.PubMedCrossRefGoogle Scholar
  10. 10.
    Salari Sharif P, Abdollahi M, Larijani B 2011 Current, new and future treatment for osteoporosis. Rheumatol Int 31:289–300.PubMedCrossRefGoogle Scholar
  11. 11.
    Eisman JA, Bone HG, Hosking DJ, et al 2011 Odanacati b i n the treatment of postmenopausal women with low bone mineral density: three-year continued therapy and resolution of effect. J Bone Miner Res 26:242–251.PubMedCrossRefGoogle Scholar
  12. 12.
    Padhi D, Jang G, Stouch B, Fang L, Posvar E 2011 Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res 26:19–26.PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG 2012

Authors and Affiliations

  1. 1.Francesco Bertoldo, Dipartimento di MedicinaUniversità degli Studi di Verona, Policlinico G.B. RossiVeronaItalia

Personalised recommendations